These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 33542080)
1. Gene Expression-Based Prediction of Neoadjuvant Chemotherapy Response in Early Breast Cancer: Results of the Prospective Multicenter EXPRESSION Trial. Edlund K; Madjar K; Lebrecht A; Aktas B; Pilch H; Hoffmann G; Hofmann M; Kolberg HC; Boehm D; Battista M; Seehase M; Stewen K; Gebhard S; Cadenas C; Marchan R; Brenner W; Hasenburg A; Koelbl H; Solbach C; Gehrmann M; Tanner B; Weber KE; Loibl S; Sachinidis A; Rahnenführer J; Schmidt M; Hengstler JG Clin Cancer Res; 2021 Apr; 27(8):2148-2158. PubMed ID: 33542080 [TBL] [Abstract][Full Text] [Related]
2. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis. Cheong JH; Yang HK; Kim H; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Kim HY; Lee J; Choi SH; Hong S; Kim JW; Choi YY; Hyung WJ; Jang E; Kim H; Huh YM; Noh SH Lancet Oncol; 2018 May; 19(5):629-638. PubMed ID: 29567071 [TBL] [Abstract][Full Text] [Related]
3. MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancer. Raychaudhuri M; Bronger H; Buchner T; Kiechle M; Weichert W; Avril S Breast Cancer Res Treat; 2017 Apr; 162(3):511-521. PubMed ID: 28181130 [TBL] [Abstract][Full Text] [Related]
4. Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR). Gampenrieder SP; Peer A; Weismann C; Meissnitzer M; Rinnerthaler G; Webhofer J; Westphal T; Riedmann M; Meissnitzer T; Egger H; Klaassen Federspiel F; Reitsamer R; Hauser-Kronberger C; Stering K; Hergan K; Mlineritsch B; Greil R Breast Cancer Res; 2019 Jan; 21(1):19. PubMed ID: 30704493 [TBL] [Abstract][Full Text] [Related]
5. Pathological complete response in invasive breast cancer treated by skin sparing mastectomy and immediate reconstruction following neoadjuvant chemotherapy and radiation therapy: Comparison between immunohistochemical subtypes. Barrou J; Bannier M; Cohen M; Lambaudie E; Gonçalves A; Bertrand P; Buttarelli M; Opinel P; Sterkers N; Tallet A; Zinzindohoué C; Houvenaeghel G Breast; 2017 Apr; 32():37-43. PubMed ID: 28033508 [TBL] [Abstract][Full Text] [Related]
6. The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study. Di Cosimo S; Triulzi T; Pizzamiglio S; De Cecco L; de Azambuja E; Fumagalli D; Putzai L; Harbeck N; Izquierdo M; Peña L; Daidone MG; Huober J; Gori S; Cinieri S; Torri V; Baselga J; Piccart M; de Braud FG; Apolone G; Verderio P; Tagliabue E Eur J Cancer; 2019 Sep; 118():1-9. PubMed ID: 31284184 [TBL] [Abstract][Full Text] [Related]
7. Ultrasound-based prediction of pathologic response to neoadjuvant chemotherapy in breast cancer patients. Baumgartner A; Tausch C; Hosch S; Papassotiropoulos B; Varga Z; Rageth C; Baege A Breast; 2018 Jun; 39():19-23. PubMed ID: 29518677 [TBL] [Abstract][Full Text] [Related]
8. The use of a second core needle biopsy to predict response to neoadjuvant chemotherapy in breast cancer patients, especially in the HER2-positive population. Zhang Y; Shen J; Wu S; Zhou Y; Shao Z; Liu G Surgery; 2020 Dec; 168(6):1115-1121. PubMed ID: 32917430 [TBL] [Abstract][Full Text] [Related]
9. Molecular types and neoadjuvant chemotherapy in patients with breast cancer- while molecular shifting is more common in luminal a tumors, the pathologic complete response is most frequently observed in her-2 like tumors. Salim DK; Mutlu H; Eryilmaz MK; Musri FY; Tural D; Gunduz S; Coskun HS Asian Pac J Cancer Prev; 2014; 15(21):9379-83. PubMed ID: 25422228 [TBL] [Abstract][Full Text] [Related]
10. Early progression of breast cancer during neoadjuvant chemotherapy may predict poorer prognoses. Myller S; Ipatti P; Jääskeläinen A; Haapasaari KM; Jukkola A; Karihtala P Acta Oncol; 2020 Sep; 59(9):1036-1042. PubMed ID: 32394761 [No Abstract] [Full Text] [Related]
11. Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer. Villegas SL; Darb-Esfahani S; von Minckwitz G; Huober J; Weber K; Marmé F; Furlanetto J; Schem C; Pfitzner BM; Lederer B; Engels K; Kümmel S; Müller V; Mehta K; Denkert C; Loibl S Breast Cancer Res Treat; 2018 Feb; 168(1):179-187. PubMed ID: 29177689 [TBL] [Abstract][Full Text] [Related]
12. Analysis of the relevance between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer as well as its prognostic factors. Li F; Ma L; Geng C; Liu C; Deng H; Yue M; Ding Y; Wang X; Liu Y Pathol Res Pract; 2018 Aug; 214(8):1166-1172. PubMed ID: 29945816 [TBL] [Abstract][Full Text] [Related]
13. Ki-67 labeling index as a predictor of response to neoadjuvant chemotherapy in breast cancer. Jain P; Doval DC; Batra U; Goyal P; Bothra SJ; Agarwal C; Choudhary DK; Yadav A; Koyalla VPB; Sharma M; Dash P; Talwar V Jpn J Clin Oncol; 2019 Apr; 49(4):329-338. PubMed ID: 30753543 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer. Soliman H; Wagner S; Flake DD; Robson M; Schwartzberg L; Sharma P; Magliocco A; Kronenwett R; Lancaster JM; Lanchbury JS; Gutin A; Gradishar W Ann Surg Oncol; 2020 Mar; 27(3):765-771. PubMed ID: 31907749 [TBL] [Abstract][Full Text] [Related]
15. Response and Prognosis of Docetaxel and Cyclophosphamide as Neoadjuvant Chemotherapy in ER Hayashi N; Yagata H; Tsugawa K; Kajiura Y; Yoshida A; Takei J; Yamauchi H; Nakamura S Clin Breast Cancer; 2020 Dec; 20(6):462-468. PubMed ID: 33046356 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of Therapeutic Target Gene Expression Based on Residual Cancer Burden Classification After Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer. Takahashi Y; Iwamoto T; Suzuki Y; Kajiwara Y; Hatono M; Tsukioki T; Kawada K; Kochi M; Ikeda H; Shien T; Taira N; Matsuoka J; Doihara H; Toyooka S Clin Breast Cancer; 2020 Apr; 20(2):117-124.e4. PubMed ID: 31570267 [TBL] [Abstract][Full Text] [Related]
17. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer. Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750 [TBL] [Abstract][Full Text] [Related]
18. Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer. Cottu P; D'Hondt V; Dureau S; Lerebours F; Desmoulins I; Heudel PE; Duhoux FP; Levy C; Mouret-Reynier MA; Dalenc F; Frenel JS; Jouannaud C; Venat-Bouvet L; Nguyen S; Ferrero JM; Canon JL; Grenier J; Callens C; Gentien D; Lemonnier J; Vincent-Salomon A; Delaloge S Ann Oncol; 2018 Dec; 29(12):2334-2340. PubMed ID: 30307466 [TBL] [Abstract][Full Text] [Related]
19. Usefulness of serum M30 and M65 levels to predict response to neoadjuvant chemotherapy in patients with breast cancer. Turk HM; Aliyev A; Celik RS; Seker M; Coban E; Demir T; Baydas T; Kocyigit A Curr Probl Cancer; 2020 Feb; 44(1):100497. PubMed ID: 31371034 [TBL] [Abstract][Full Text] [Related]